Hikal Q4 Results
- BSE: 524735
- NSE: HIKAL
- ISIN: INE475B01022
- Sector: Biotechnology & Drugs
BSE
351
-16.50 (-4.49%)
-16.50 (-4.49%)Volume29.49 K
Updated: Fri 24 Jan, 2025 | 15:29:56
NSE
348.60-18.85 (-5.13%)
-18.85 (-5.13%)Volume1.86 L
Updated: Fri 24 Jan, 2025 | 15:50:05
Technical Trends
Long TermConsiders price movement over the last 6 months
Not Available
Short TermConsiders price movement over the last 1-2 weeks
Not Available
- Bearish
- Moderately Bearish
- Neutral
- Moderately Bullish
- Bullish
Insight: Trends unavailable at the moment.
Q4 Results Highlights
Note: Comparison is on QoQ basis
Quarterly - Hikal Q4 Results
*All figures in crores except per share values
| Fiscal Period | Mar 24 | Dec 23 | QoQ Comp | Mar 23 | YoY Comp |
|---|---|---|---|---|---|
| Total Revenue | 514.10 | 447.57 | 14.86% | 545.29 | -5.72% |
| Selling/ General/ Admin Expenses Total | 63.78 | 61.31 | 4.03% | 57.84 | 10.27% |
| Depreciation/ Amortization | 32.34 | 28.97 | 11.64% | 26.83 | 20.53% |
| Other Operating Expenses Total | 121.61 | 114.68 | 6.04% | 117.70 | 3.32% |
| Total Operating Expense | 451.98 | 411.78 | 9.76% | 482.11 | -6.25% |
| Operating Income | 62.12 | 35.79 | 73.57% | 63.18 | -1.67% |
| Net Income Before Taxes | 47.33 | 21.61 | 119.00% | 48.58 | -2.57% |
| Net Income | 33.97 | 16.14 | 110.48% | 35.99 | -5.61% |
| Diluted Normalized EPS | 2.75 | 1.31 | 110.25% | 2.91 | -5.47% |